• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » Time to Talk About Naloxone [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts, Android, or Stitcher.

Time to Talk About Naloxone [60 Sec Psych]

October 17, 2020

New labeling from the FDA requires physicians to discuss naloxone with patients or caregivers they are prescribing opioids to. The new guideline also recommends that we prescribe naloxone to anyone who is at risk for opioid overdose, even if we aren’t prescribing them an opioid. That would include patients with a history of opioid overdose and those who use the drugs recreationally.


Published On: 10/17/20


Duration: 2 minutes, 6 seconds


Episode Notes: Naloxone 2 mg/2 ml pre-filled Luer lock–ready needleless syringes with a mucosal atomizer or Narcan nasal spray 4 mg


Transcript: 


Naloxone is an opioid antagonist that can save lives when used for opioid overdose. Most of these fatalaties are accidental, and can happen when the patient takes a little more than prescribed to ease their pain or unwittingly combines the opioid with a respiratory suppressant like benzos or alcohol. Now, new labeling from the FDA requires physicians to discuss naloxone with patients or caregivers they are prescribing opioids to. The new guideline also recommends that we prescribe naloxone to anyone who is at risk for opioid overdose, even if we aren’t prescribing them an opioid. That would include patients with a history of opioid overdose and those who use the drugs recreationally. 

Naloxone can be given IV or IM, but the intranasal route is what we prescribe to outpatients. Most states allow you to prescribe naloxone to family members even if you’ve never met or assessed the family – which makes sense since the antagonist is intended for use on your patient. The antagonist only lasts 30-60 minutes, so the family may need to give multiple doses to keep the patient alive while they await EMS. And – while it may save a life – the patient may not thank the family right away. Naloxone will usually precipitate opioid withdrawal symptoms like estlessness, agitation, nausea, vomiting, a fast heart rate, and sweating.

Naloxone was patented in 1961 and approved for opioid overdose in the United States in 1971. I’ve included exact prescribing directions for the nasal version in the episode notes.

Got feedback? Take the podcast survey.

Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop For Total Access

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto22709844.jpg
    General Psychiatry

    Psychopharm Commandment #10: Don’t Fear these Meds

    Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.